Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Go back to Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 14.69 -0.36 (2.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.05 | 52 Week High | $19.40 | |||
| Open | $15.05 | 52 Week Low | $12.50 | |||
| Day High | $15.40 | P/E | N/A | |||
| Day Low | $14.67 | EPS | $0.00 | |||
| Volume | 53,731 | |||||
